Operating Income (Loss) in USD of Elicio Therapeutics, Inc. from Q1 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Elicio Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q1 2020 to Q3 2025.
  • Elicio Therapeutics, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$8.05M, a 22.2% increase year-over-year.
  • Elicio Therapeutics, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$42.3M, a 3.54% decline year-over-year.
  • Elicio Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$45M, a 25.9% decline from 2023.
  • Elicio Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$35.7M, a 50.6% decline from 2022.
  • Elicio Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$23.7M, a 39.6% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Elicio Therapeutics, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$42.3M -$8.05M +$2.3M +22.2% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025
Q2 2025 -$44.6M -$10.1M +$833K +7.63% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 -$45.5M -$10.7M -$495K -4.83% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025
Q4 2024 -$45M -$13.5M -$4.09M -43.5% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025
Q3 2024 -$40.9M -$10.3M +$427K +3.96% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025
Q2 2024 -$41.3M -$10.9M -$3.15M -40.5% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 -$38.2M -$10.2M -$2.44M -31.2% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025
Q4 2023 -$35.7M -$9.39M -$12.1M -441% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025
Q3 2023 -$23.6M -$10.8M -$5M -86.7% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024
Q2 2023 -$18.6M -$7.78M -$1.55M -24.8% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024
Q1 2023 -$17.1M -$7.81M +$6.68M +46.1% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024
Q4 2022 -$23.7M $2.75M -$11.9M -81.2% 01 Oct 2022 31 Dec 2022 10-K 29 Mar 2024
Q3 2022 -$11.9M -$5.77M +$9.99M +63.4% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023
Q2 2022 -$21.8M -$6.23M +$12M +65.8% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 -$33.9M -$14.5M +$5.45M +27.4% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023
Q4 2021 -$39.3M $14.6M +$28.5M 01 Oct 2021 31 Dec 2021 10-K 17 Mar 2023
Q3 2021 -$67.8M -$15.8M -$4.17M -36% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 -$63.6M -$18.2M -$975K -5.65% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q1 2021 -$62.6M -$19.9M -$7.37M -58.6% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022
Q4 2020 -$55.3M -$13.9M 01 Oct 2020 31 Dec 2020 10-K 30 Mar 2022
Q3 2020 -$11.6M 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 -$17.3M 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021
Q1 2020 -$12.6M 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021

Elicio Therapeutics, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$45M -$9.24M -25.9% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025
2023 -$35.7M -$12M -50.6% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025
2022 -$23.7M +$15.6M +39.6% 01 Jan 2022 31 Dec 2022 10-K 29 Mar 2024
2021 -$39.3M +$16M +28.9% 01 Jan 2021 31 Dec 2021 10-K 17 Mar 2023
2020 -$55.3M 01 Jan 2020 31 Dec 2020 10-K 30 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.